Judith Balmaña, Peter A Fasching, Fergus J Couch, Suzette Delaloge, Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Gonçalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, Antonio Antón-Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon
PURPOSE: The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), with median progression-free survival (PFS) of 8.11 months, which was similar to that in the olaparib arm of the phase III OlympiAD trial (7.03 months). This prespecified analysis provides final overall survival (OS) and safety data. METHODS: The open-label, single-arm LUCY trial of olaparib (300 mg, twice daily) enrolled adults with gBRCAm or somatic BRCA-mutated (sBRCAm), HER2-negative mBC...
December 19, 2023: Breast Cancer Research and Treatment